Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 36M | 35M | 35M | 37M | 25M |
| Gross Profit | 9M | 12M | 23M | 19M | 11M |
| Operating Income | -11M | -2M | 9M | 9M | 3M |
| EBITDA | -2M | 17M | 15M | 13M | 6M |
| Net Income | -22M | 4M | 11M | 5M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.1777
-6.77% today
1Y Change
+100.00%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vext Science, Inc. (VEXTF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $0.18 and up 100.0% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of +45.2%, EPS growth of +20.5%, a dividend yield of 0.0%. What stands out right now is revenue +45.2%, EPS +20.5%, free cash flow +354.5% with operating margin -16.4% and ROIC -8.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VEXTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VEXTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VEXTF Max Drawdown
-45.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VEXTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$25.2M
-32.4% YoY
FY Net Income
$2.1M
-57.4% YoY
Free Cash Flow
-$964.9K
+86.4% YoY
Revenue Growth
+45.2%
EPS Growth
+20.5%
Gross Margin
25.4%
Net Margin
-35.2%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 36M | 35M | 35M | 37M | 25M |
| Gross Profit | 9M | 12M | 23M | 19M | 11M |
| Operating Income | -11M | -2M | 9M | 9M | 3M |
| EBITDA | -2M | 17M | 15M | 13M | 6M |
| Net Income | -22M | 4M | 11M | 5M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 9M | 6M | 6M | 2M |
| Total Assets | 137M | 150M | 121M | 84M | 55M |
| Total Liabilities | 61M | 55M | 49M | 24M | 19M |
| Shareholder Equity | 76M | 95M | 72M | 59M | 36M |
| Total Debt | 40M | 39M | 38M | 14M | 11M |
| Net Debt | 35M | 30M | 32M | 8M | 10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
-73.5% YoY
Capital Expenditures
4M
+78.4% YoY
Free Cash Flow
965K
+86.4% YoY
Key ratios
Gross Margin
25.4%
Operating Margin
-16.4%
Net Margin
-35.2%
ROE
-27.2%
Debt / Equity
0.63x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.